Global Mircobiome Therapeutics Market Size, Dynamics, Regional Market Share, Top Key Players, Latest Trends, Growth Factors, Industry Stats, Historic Market, Business Intelligence, Business Research Reports, Competitive Intelligence 2013 to 2017 and Forecast 2018 to 2024
Microbiome is genetic material of all microbes such as bacteria, virus, fungi and protozoa that live on and inside the human body. Every part of the body has different types of microbes. For example, about a third bacteria in the gut are Bacteriodes species, while Streptococcus species are dominant about oral health. Microbiomes plays significant role in human health and disease conditions.
Increase in evidence about the direct relationship of microbiome in treating life style diseases, autoimmune diseases such as Crohn’s, inflammatory bowel disease (IBS) conditions are filling the growth of the market. Currently, few drugs are available in the market to treat these conditions. Furthermore, microbiome therapies are safer than conventional treatments. Microbiome therapeutics did not possess any side-effects. However, the growth of the market over the forecast period may be hampered.
A sample of this report is available upon request @
Mircobiome Therapeutics Market has been segmented based on Product Type, and Disease Indication
Based on the product type, Mircobiome Therapeutics Market has been segmented into the following:
- probiotics
- Prebiotics
- Synbiotics (Combination of Prebiotics and Probiotics)
Based on Disease Indication, Mircobiome Therapeutics Market has been segmented into the following:
- Digestive related disorders
- o Crohn’s disease
- o Inflammatory Bowel Disease (IBD)
- Irritable Bowel Syndrome (IBS)
- Others
- Metabolic Disorders
- Obesity
- o Diabetes
- Others
- Respiratory Infections
- Cancer
- Immune system
- Oral Diseases
- Skin Infections
- Others
To view TOC of this report is available upon request @
Mircobiome Therapeutics Market is still nascent stage, currently approved to treat various therapeutic conditions. Start-ups are very active in the Mircobiome Therapeutics Market in terms of product launches, research and development activities. However, bigger players in Mircobiome Therapeutics Market are focused on providing funding, collaborating and acquiring smaller players to promote research activities. Furthermore, venture capitalists and government organizations are actively involved in funding and encouraging the research activities. Launch of microbiome therapeutics products on the market. For instance, in May 2014, Pfizer has entered into an agreement with Second Genome to conduct research on obesity and metabolic disorders. In April 2016, Company raised $ 42.6 million in Series B funding led by Pfizer Venture Investments and Roche Venture Fund. The Funding Amount Will Be Used to Conduct Clinical Investigation on SGM-109, a small molecule inhibitor of microbiome mediated target to address inflammatory and pain conditions in ulcerative colitis. In February 2016, Synlogic raised US $ 40 million in Series B from OrbisMed Healthcare Fund Management to expand its research programs on inflammatory bowel disease conditions and to develop therapeutics for in vitro errors of metabolism of urea cycle disorder and phenylketonuria conditions. a small molecule inhibitor of microbiome mediated target to address inflammation and pain conditions in ulcerative colitis. In February 2016, Synlogic raised US $ 40 million in Series B from OrbisMed Healthcare Fund Management to expand its research programs on inflammatory bowel disease conditions and to develop therapeutics for in vitro errors of metabolism of urea cycle disorder and phenylketonuria conditions. a small molecule inhibitor of microbiome mediated target to address inflammation and pain conditions in ulcerative colitis. In February 2016, Synlogic raised US $ 40 million in Series B from OrbisMed Healthcare Fund Management to expand its research programs on inflammatory bowel disease conditions and to develop therapeutics for in vitro errors of metabolism of urea cycle disorder and phenylketonuria conditions.
Need more information about this report @
Geographically market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Europe accounted for by North America. Active involvement of government organization owing to the research on microbiome in European countries. For instance, MetaGenoPolis (MGP) program entitled „Investisements d’Avenir“ to understand the human microbiome impact on human health. In June 2014, MyNewGut project received funding from the European Union to develop dietary interventions that have an impact on controlling obesity, diabetes, and cardiovascular disease conditions. In Asia-Pacific region, research on microbiome therapeutics is also actively carried out by research institutes through government funding programs. In 2010, Korean Microbiome Diversity Using Korean Twin Cohort Project was funded by National Research Foundation of Korea. The aim of the project is to identify the microbiome and genes that are associated with human diseases.
Global Mircobiome Therapeutics Market dominated by key players such as Johnson & Johnson, Pfizer Inc., AB biotics, Enterome, Seres Therapeutics, Vedanta Biosciences, Eligo Bioscience, 4D Pharma plc, Synlogic, TargEDys, Second Genome, LNC research & development, Takeda Pharmaceutical Company Ltd, PROBI, and Ritter Pharmaceuticals.
Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/global-mircobiome-therapeutics-market/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firms, which follows a holistic approach to solve the needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and making better decisions. We provide consulting, syndicated and customized market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com